Compare ARDX & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | GERN |
|---|---|---|
| Founded | 2007 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 975.9M | 1.0B |
| IPO Year | 2014 | 1996 |
| Metric | ARDX | GERN |
|---|---|---|
| Price | $3.42 | $1.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 3 |
| Target Price | ★ $15.14 | $2.17 |
| AVG Volume (30 Days) | 3.9M | ★ 8.7M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,607,000.00 | $1,065,000.00 |
| Revenue This Year | $37.75 | $26.91 |
| Revenue Next Year | $34.24 | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $1.04 |
| 52 Week High | $8.40 | $2.01 |
| Indicator | ARDX | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 24.11 | 38.92 |
| Support Level | N/A | $1.24 |
| Resistance Level | $3.92 | $1.32 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 14.53 | 11.43 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.